31 May 2017
A ground-breaking ceremony of a pharmaceutical factory was held on Tuesday in Vorsino technology park located near the Russian city of Kaluga. American company Pfizer is an investor of the enterprise's building project.
According to TASS news agency, the main partner of the project is NovaMedica, a portfolio company of the Russian government-owned company Rusnano engaged in the development of nanotechnology.
Speaking at the ceremony, Chairman of Rusnano’s Board Anatoly Chubais said that NovaMedica has barely started the construction of its factory, but it is already having the sales volume amounting to 1 billion rubles on the Russian market.
A third of medical drugs that will be manufactured at the enterprise under a license of Pfizer are not currently produced in the territory of Russia.
PrintNovaMedica to localize in Russia one of the most popular anti-migraine drugs in the world
21 March 2023
Merry Christmas and Happy New Year!
27 December 2022
15 December 2022
In April 2023 drugs worth of 54.3 billion rubles were produced in Russia
09 June 2023
In Russia, child mortality is declining, while life expectancy is growing
09 June 2023
How can biopharma strengthen its resilience?
08 June 2023
Sergey Glagolev: Foreign companies are interested in conducting clinical trials in Russia
08 June 2023